Researchers from IDIBELL and CIBERSAM have discovered how alterations in the connectivity of two regions of the brain represents a potential biomarker for Alzheimer's vulnerability.
Schizophrenia is a very heterogeneous disease, patients who suffer this may present a variety of symptoms. In addition, there is currently no analytical or imaging test that confirms the diagnosis. Th...
Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new funding. The funding w...
Dr. Eduard Parellada, member of the Schizophrenia Unit led by Dr. Miquel Bernardo, was awarded with the SEPB Reference Investigator Prize. It has been because of a collaborative study, funded by the F...
The awarded project is about the status of preferences of the patients in the field of mental health in Catalonia, and it will be elaborated in collaboration with Federació Veus - Entitats Catalanes ...